Loading the section…

SLDB: financial statements from SEC — TradeAlmanac

SLDB

Solid Biosciences Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	31/03/2026	30/09/2025	30/06/2025	31/03/2025	30/09/2024	30/06/2024
Research and development	46M	39M	32M	31M	27M	19M
Selling, general and administrative	11M	9M	9M	9M	8M	8M
Operating expenses	57M	48M	42M	40M	35M	28M
Operating income	−57M	−48M	−42M	−40M	−35M	−28M
Interest expense	—	—	—	—	—	88,000
Net income	−57M	−46M	−39M	−39M	−33M	−25M
Earnings per share	−0.52	−0.48	−0.42	−0.59	−0.79	−0.61
Earnings per share, diluted	−0.52	−0.48	−0.42	−0.42	−0.79	−0.61
Weighted average shares	110M	94M	94M	66M	41M	41M
Weighted average shares, diluted	110M	94M	94M	66M	41M	41M

Balance sheet

Metric	31/03/2026	31/12/2025	30/09/2025	30/06/2025	31/03/2025	31/12/2024	30/09/2024	30/06/2024
Cash and equivalents	297M	60M	61M	139M	211M	80M	64M	96M
Current assets	397M	205M	245M

Cash flow

Metric	31/03/2026	31/03/2025
Operating cash flow	−47M	−32M
Depreciation and amortisation	395,000	407,000
Share-based compensation	5M	3M
Capital expenditure	165,000	126,000
Investing cash flow	45M	−27M
Financing cash flow	239M

Amounts in USD unless stated otherwise. Data: US exchange trading and company filings with the regulator